CoChat

Neurological sequelae of cancer immunotherapies and targeted therapies

Wick, Wolfgang, Hertenstein, Anne, Platten, Michael · 2016 · The Lancet Oncology

The DOI matches its Crossref record; 73 of the 75 references it cites were found in a registry or an index.

Abstract

Neurological complications of cancer and of anticancer treatments can be substantially disabling to patients, especially with classic chemotherapies. As a rare but important complication, targeted therapies might also result in similar unwanted effects, partly because inhibition of VEGF is a common downstream effect. Therapeutic antibodies, such as the CD20-depleting antibody rituximab, and underlying haematological malignancies, can induce long-lasting cellular immunosuppression, predisposing patients to opportunistic CNS infections, such as progressive multifocal leukoencephalopathy, where treatment-induced recovery can result in severe reconstitution of immune inflammatory syndromes of the central nervous system. Immune-related neurological adverse events, particularly from immune-activating checkpoint inhibitors, occur as a result of immune activation, resulting in organ-specific autoimmune-like disease. The prevalence of immune-related neurological adverse events might only be about 1%-a low prevalence compared with toxicities in other organs-but it constitutes new patterns of neurological toxic forms, which could result in considerable morbidity and fatal outcomes. Clinicians should be aware of treatment-associated neurotoxicity, and consider discontinuation of the drug with parallel supportive measures to help patients.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(16)30571-x

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 73 references

Research works printed but not linked: 1

  1. Dirix, 2010, Arterial hypertension induced by vascular endothelial growth factor interfering agents: mechanisms and management, Belg J Med Oncol, 4, 159

Cited by

See all 87

Metadata

Authors
Wick, W., Hertenstein, A., & Platten, M.
Affiliations
German Cancer Research Center (DE)
Corresponding author
Wick, Wolfgang
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2016-12
Volume
17
Issue
12
Pages
e529-e541
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2557614618
Cited by
87
References
75
Citations by year
2026: 6 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 13 · 2020: 17 · 2019: 12 · 2018: 13 · 2017: 7
FWCI
1.07
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Boehringer Ingelheim
  • Pfizer
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords
cancer immunotherapy, targeted therapy, VEGF inhibition, rituximab, progressive multifocal leukoencephalopathy, opportunistic CNS infection, immune checkpoint inhibitors, immune-related adverse events, chemotherapy-induced neurotoxicity, hematologic malignancies
MeSH terms
Brain Diseases, Cerebellar Diseases, Humans, Immunotherapy, Neoplasms, Nervous System Diseases, Seizures, Leukoencephalopathies, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neurological sequelae of cancer immunotherapies and targeted therapies. https://app.cochat.ai/papers/10.1016/s1470-2045(16)30571-x
The paper
Wick, W., Hertenstein, A., & Platten, M. (2016). Neurological sequelae of cancer immunotherapies and targeted therapies. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(16)30571-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.